Back to search results

Brain Training for Opioid Use Disorder

This study is testing a new type of brain training called Bias Modification Biofeedback for people with Opioid Use Disorder (OUD). This device uses an EEG (electroencephalogram), which measures brain waves, to help you reduce your focus on drug-related things and pay more attention to pleasant, non-drug scenes. The study wants to see if this training can change how your brain responds to drug cues and how quickly you react to them. You can join if you are 18-65 years old, have an OUD diagnosis, are in treatment, and can read at a 6th-grade level or higher. The study plans to enroll 40 participants.

Study design
This is an interventional study with a planned enrollment of 40 participants. The phase of the study is not specified.
What's involved
You would participate in a biofeedback session, which lasts about 30 minutes. You would also need to provide contact information for potential follow-up visits.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured from pre- to post-biofeedback session on the same day. The study mentions potential follow-up visits, but no specific duration is given.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06870110

Brain Training for Substance Use Disorders

Recruiting
NAAges 18–65InterventionalTreatment
Neurotype Inc.
~40 participants
Updated 2025-03-11 on ClinicalTrials.gov
What's tested:Bias Modification Biofeedback

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in ERP-Based Classification of Opioid-Related Attention Bias (Probability Score)
Measured over Pre- to post-biofeedback session (same day, approximately 30 minutes)
+1 more outcome measured

Conditions

Opioid Use Disorder

Explore related trials

Opioid Use Disorder

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Justin Anker, PhD · PRINCIPAL_INVESTIGATOR · University of Minnesota
  • Scott Burwell, PhD · STUDY_DIRECTOR · Neurotype Inc.

Who to contact

Scott Burwell, PhD
[email protected]
612-790-9304
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Admitted into chemical treatment with opioid use being a reason for treatment;
DSM-IV-TR diagnosis of OUD;
Ability to provide informed consent;
A minimum of a 6th grade reading level; and
Able and willing to provide own contact information for follow-up visit(s).
Age- and gender-matched to an OUD patient participant in the study;
Ability to provide informed consent;
A minimum of a 6th grade reading level;
Able and willing to provide own contact information for follow-up visit(s).

Exclusion

Refusal or inability to consent;
Pregnant;
History of serious neurological illness (e.g., Chronic seizure disorder, Wernicke-Korsakoff Syndrome, Epilepsy, Any history of seizures not caused by withdrawal from substances, Other \[please specify\]);
Inability to see text and photos clearly on the computer display; and
Unwillingness to change hairstyle (e.g., braids, pony tails, dreadlocks) or remove wig to accommodate application of the EEG headset, if necessary.
Refusal or inability to consent;
Pregnant;
History of serious neurological illness (e.g., Chronic seizure disorder, Wernicke-Korsakoff Syndrome, Epilepsy, Any history of seizures, Other \[please specify\]);
Inability to see text and photos clearly on the computer display;
Current or previous problems using opioids, other prescription (prescribed or not prescribed) or illicit drugs;
Regular nicotine user (e.g., cigarette smoker, e-cig user) within the past 12 months; and
Unwillingness to change hairstyle (e.g., braids, pony tails, dreadlocks) or remove wig to accommodate application of the EEG headset, if necessary.

What this trial measures

  • Change in ERP-Based Classification of Opioid-Related Attention Bias (Probability Score)Pre- to post-biofeedback session (same day, approximately 30 minutes)

    The primary outcome will be the change in ERP-based classification scores (probability values) reflecting opioid-related attention bias. ERP voltages from all electrodes will be classified with coefficients reflecting increased amplitude in Early Posterior Negativity (150 to 300 ms), P300 complex (250 to 450 ms), and Late Positive Potential (400 to 900 ms) windows. Change in classification score from the last minus first block will be evaluated.

  • Change in Visual Probe Task Reaction Time (milliseconds) to Drug-Related StimuliPre- to post-biofeedback session (same day, approximately 30 minutes)

    The primary outcome will be the change in reaction time (milliseconds) on the Visual Probe Task, measuring attention bias toward drug-related versus neutral stimuli. Participants will complete the task before and after the biofeedback session. Attention bias is indicated by differences in reaction time when responding to probes replacing drug-related versus neutral stimuli. Improvement is reflected by reduced bias scores, calculated as the difference between reaction times to drug-related versus neutral probes. Change scores from pre- to post-session will be analyzed.